Handelsavisen
prelaunch
Companies Healthcare 2289.HK
22
2289.HK HKEX Pharmaceuticals

2289.Hk

HK$6,10
Open in Charts → Attach watcher ⌖
HKD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
658,8M HKD
P/E
EV / Rev
Div yield
5,84 %
Op margin
1,6 %
ROE
7,5 %
Net margin
1,1 %
Debt / equity
1,94
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of pharmaceutical products and related medical research.

Business. The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of pharmaceutical products and related medical research.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
7,5 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 2289.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 2289.HK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of pharmaceutical products and related medical research.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    The company maintains a market capitalization of 628.56 million CNY and a price-to-earnings ratio of 13.58, indicating a moderate valuation relative to its earnings. Its price-to-book ratio of 1.02 suggests that the market values the company's equity in line with its book value. The company's liquidity position is characterized by a current ratio of 1.09, which is slightly above 1, indicating a modest ability to meet short-term obligations. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints.

    In terms of profitability, the company's return on equity (ROE) is 7.51%, which is relatively low compared to industry benchmarks. The return on assets (ROA) is 1.17%, further indicating that the company is not efficiently utilizing its assets to generate profits. The gross profit margin is 7.53%, and the operating margin is 1.55%, both of which are below the industry median, suggesting that the company is facing challenges in maintaining profitability.

    The company's revenue is primarily concentrated in a single geographic region, with no disclosed segment breakdown. This lack of diversification increases the company's exposure to regional economic and regulatory risks. The company's revenue for the latest period was 4.38 billion CNY, with a gross profit of 330.33 million CNY and an operating income of 68.10 million CNY.

    The company's growth trajectory is modest, with a revenue of 4.38 billion CNY for the latest period. The company's net income was 46.27 million CNY, and its earnings per share (EPS) were 0.41 CNY. The company's debt-to-equity ratio is 1.94, indicating a high level of leverage, which could constrain its ability to invest in growth opportunities.

    The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could lead to liquidity constraints. The company's debt-to-equity ratio of 1.94 suggests that it is highly leveraged, which could increase its financial risk. The company's dilution risk is low, as there is no indication of significant share issuance or dilution potential.

    Recent events and filings indicate that the company has not disclosed any significant new developments or strategic initiatives. The company's latest actual EPS was 0.41 CNY, and its latest actual revenue was 4.096 billion CNY. The company's financial performance has been stable, but there are no indications of significant growth or innovation in the near term.

    Key takeaways
    • The company has a moderate valuation with a price-to-earnings ratio of 13.58 and a price-to-book ratio of 1.02.
    • The company's profitability metrics, including ROE and ROA, are below industry medians, indicating inefficiencies in asset utilization and equity returns.
    • The company's revenue is concentrated in a single geographic region, increasing its exposure to regional economic and regulatory risks.
    • The company's debt-to-equity ratio of 1.94 suggests a high level of leverage, which could constrain its ability to invest in growth opportunities.
    • The company's liquidity position is modest, with a current ratio of 1.09 and a negative net cash position after subtracting total debt.
    • The company's recent financial performance has been stable, but there are no indications of significant growth or innovation in the near term.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    HK$6,10
    Market cap
    HK$628.6M
    Enterprise value
    HK$1.07B
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    1.0x
    P / Tangible book
    1.0x
    Tangible book
    HK$616.4M
    Net cash
    -HK$441.1M
    Current ratio
    1.1
    Debt / equity
    1.9
    ROA
    1.2%
    ROE
    7.5%
    Cash conversion
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin1,6 %Below median
    Net Margin1,1 %Below median
    ROE7,5 %Above median
    D/E1,94Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Earnings
      market_price / (net_income / shares_outstanding_diluted)
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    Source documents
    • 2289.HK Market data — financials · 2026-05-26
    • Charmacy Pharmaceutical Co Ltd Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    2289.HKCanonical
    HKEX · HKD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage